Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol

Properties of FDA-approved small molecule protein kinase inhibitors

(2019) Robert Roskoski   PHARMACOLOGICAL RESEARCH

Challenges with Novel Clinical Trial Designs: Master Protocols

(2019) Michael Cecchini et al.   CLINICAL CANCER RESEARCH

SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway–Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)

(2019) Charu Aggarwal et al.   Journal of Thoracic Oncology

Brief Report: SWOG S1400B (NCT02785913), A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)

(2019) Corey J. Langer et al.   Journal of Thoracic Oncology

Brief Report: SWOG S1400C (NCT02154490)—A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-study)

(2019) Martin J. Edelman et al.   Journal of Thoracic Oncology

Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both

(2017) Janet Woodcock et al.   NEW ENGLAND JOURNAL OF MEDICINE

High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial

(2017) Christophe Massard et al.   Cancer Discovery

Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial

(2016) Tracy L. Stockley et al.   Genome Medicine

The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer

(2015) G. Middleton et al.   ANNALS OF ONCOLOGY

Lung Master Protocol (Lung-MAP)--A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400

(2015) R. S. Herbst et al.   CLINICAL CANCER RESEARCH

Squamous Cell Lung Cancer: From Tumor Genomics to Cancer Therapeutics

(2015) D. R. Gandara et al.   CLINICAL CANCER RESEARCH

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Master Protocol Concept

(2015) Mary W. Redman et al.   SEMINARS IN ONCOLOGY

Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial

(2014) C Le Tourneau et al.   BRITISH JOURNAL OF CANCER

Consensus Report of a Joint NCI Thoracic Malignancies Steering Committee: FDA Workshop on Strategies for Integrating Biomarkers into Clinical Development of New Therapies for Lung Cancer Leading to the Inception of “Master Protocols” in Lung Cancer

(2014) Shakun M. Malik et al.   Journal of Thoracic Oncology

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing

(2013) Garrett M Frampton et al.   NATURE BIOTECHNOLOGY

Comprehensive genomic characterization of squamous cell lung cancers

(2012)   NATURE

The BATTLE Trial: Personalizing Therapy for Lung Cancer

(2011) Edward S. Kim et al.   Cancer Discovery

Improving Survival for Stage IV Non-small Cell Lung Cancer: A Surveillance, Epidemiology, and End Results Survey from 1990 to 2005

(2010) Daniel Morgensztern et al.   Journal of Thoracic Oncology

I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy

(2009) AD Barker et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS